Table 1.
Sample characteristics of the S-ketamine and the control group
| Variables | Categories | S-ketamine group | Control group |
|---|---|---|---|
| Group size a | 8 | 8 | |
| Gender a | Female | 4 | 5 |
| Male | 4 | 3 | |
| Age b | 52.13 ± 13.25 | 54.63 ± 13.23 | |
| Diagnosis at admission a | Breast cancer | 0 | 3 |
| Cancer of unknown primary | 1 | 1 | |
| Cervical cancer | 1 | 1 | |
| Glioblastoma | 1 | 0 | |
| Colorectal cancer | 1 | 0 | |
| HIV | 1 | 0 | |
| Liver cancer | 0 | 1 | |
| Lung cancer | 2 | 0 | |
| Ovarian cancer | 0 | 1 | |
| Pancreatic cancer | 0 | 1 | |
| Prostate cancer | 1 | 0 | |
| Length of stay in SPCU (days) b | 14.63 ± 7.69 | 13.00 ± 3.42 | |
| Mode of discharge a | Home | 0 | 4 |
| Hospice | 3 | 1 | |
| Other clinic | 0 | 2 | |
| Died on the ward | 5 | 1 | |
| Points of measurement (days) b | T1 | 5.63 ± 2.88 | 3.38 ± 1.06 |
| T2 | 8.00 ± 3.70 | 7.50 ± 2.45 | |
| Z1 | 5.88 ± 2.90 | 3.38 ± 1.06 | |
| Z2 | 6.88 ± 2.90 | 4.38 ± 1.06 | |
| STADI anxiety b | T1 | 68.88 ± 11.01 | 57.38 ± 13.38 |
| T2 | 55.63 ± 11.73 | 57.50 ± 12.46 | |
| STADI depression b | T1 | 66.38 ± 10.88 | 59.25 ± 12.51 |
| T2 | 57.75 ± 12.75 | 59.00 ± 13.40 | |
| STADI global b | T1 | 68.38 ± 8.80 | 59.38 ± 13.66 |
| T2 | 57.38 ± 11.87 | 59.00 ± 13.27 | |
| Pain b | Z1 | 3.88 ± 1.64 | 2.88 ± 2.10 |
| Z2 | 3.50 ± 1.77 | 2.75 ± 1.67 | |
| Restlessness/anxiety c | Z1 | 1.00 (1.00–1.75) | 1.00 (0–1.75) |
| Z2 | 1.00 (1.00–1.00) | 1.00 (0–1.75) |
a= n
b= M ± SD
c= Mdn (IQR)